Selected article for: "base excess and treatment group"

Title: Research Communications of the 27(th) ECVIM-CA Congress: Intercontinental, Saint Julian's, Malta, 14th to 16th September 2017
  • Document date: 2017_11_7
  • ID: roslkxeq_61
    Snippet: The treatment led to significant and gradual decreases in lactate and d-dimer (P < 0.01; from 5.6 AE 1.9 mmol/L to 1.8 AE 1.0 and from 7.4 AE 6.8 to 1.2 AE 1.1 lg/mL, respectively) but significantly increased SpO 2 and base excess (P < 0.01; from 87 AE 5.3 to 95 AE 1.8 % and from À8.4 AE 3.2 to À3.1 AE 1.9 mmol/L, respectively) in the patients. Compared to controls, the treatment group exhibited statistically significant changes in only lactate.....
    Document: The treatment led to significant and gradual decreases in lactate and d-dimer (P < 0.01; from 5.6 AE 1.9 mmol/L to 1.8 AE 1.0 and from 7.4 AE 6.8 to 1.2 AE 1.1 lg/mL, respectively) but significantly increased SpO 2 and base excess (P < 0.01; from 87 AE 5.3 to 95 AE 1.8 % and from À8.4 AE 3.2 to À3.1 AE 1.9 mmol/L, respectively) in the patients. Compared to controls, the treatment group exhibited statistically significant changes in only lactate level (P = 0.02) and SpO 2 (P = 0.016). However, treatment of TXA 2 synthase inhibitor showed the tendency to improve the other variables, such as NT-proBNP and tricuspid regurgitant flow, implicating the potential role of TXA 2 synthase inhibitor in pulmonary vascular impedance. Abnormal behavior such as licking footpads and joints has been reported to be a putative side effect of the treatment in one case.

    Search related documents:
    Co phrase search for related documents
    • base excess and treatment effect: 1
    • base excess and treatment group: 1, 2
    • control compare and potential role: 1
    • control compare and treatment effect: 1, 2
    • control compare and treatment group: 1, 2, 3, 4, 5, 6, 7